Nucleic Acid Therapeutics Market Expected to Hit USD 14.42 Billion by 2032, Fueled by Increasing Research and Development in Nucleic Acid-Based Drugs | DataM Intelligence

Leander, Texas and TOKYO, Japan - The Global Nucleic Acid Therapeutics Market was valued at US$ 5.64 billion in 2024 and is projected to reach US$ 14.42 billion by 2032, growing at a robust CAGR of 10.9% from 2025 to 2032, according to a DataM Intelligence report.

Growth is driven by rising demand for advanced gene-based therapies, increasing prevalence of genetic and chronic diseases, and rapid advancements in RNA- and DNA-based drug technologies. Strong pipeline developments, higher R&D investments, and expanding approvals for nucleic acid therapeutics are further boosting market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/nucleic-acid-therapeutics-market?ram

United States / North America: Key Industry Developments

✅ June 2025: Novartis AG acquired Regulus Therapeutics Inc. to enhance its RNA-targeted drug development capabilities, aiming to accelerate new nucleic acid therapeutics for rare and chronic diseases.

✅ May 2025: Significant product approvals included those using advanced drug delivery technologies such as Halozyme's Enhanze, with Bristol-Myers Squibb's Opdivo and Johnson & Johnson's DARZALEX among notable therapeutics benefiting from this innovation.

✅ January 2025: The FDA approved TRYNGOLZ (olezarsen) by Ionis Pharmaceuticals for familial chylomicronemia syndrome, marking a milestone in antisense oligonucleotide therapy application.

Asia Pacific / Japan: Key Industry Developments

✅ November 2025: The nucleic acid therapeutics market in Japan showed strong interest in AI-augmented RNA drug discovery and precision delivery systems as part of innovation trends, driven by increased R&D investments.

✅ July 2025: Biotech companies such as Neubase Therapeutics and Thermo Fisher Scientific launched nucleic acid-based therapies targeted at monogenetic disorders, signaling advanced treatment options emerging in the region.

✅ March 2025: Japan's pharmaceutical sector has increasingly integrated AI technologies in nucleic acid therapy research, focusing on addressing genetic and chronic diseases with personalized medicine approaches.

Key Mergers and Acquisitions (2025):

✅ Novartis AG - acquired Regulus Therapeutics Inc. in June 2025 to reinforce its RNA-targeted drug development capabilities, expanding its portfolio in nucleic acid therapeutics for precision medicine and rare diseases.​

✅ Aldevron - partnered with Acuitas Therapeutics in May 2024, enhancing mRNA LNP encapsulation capabilities to strengthen its position in nucleic acid therapeutic manufacturing, facilitating growth in 2025.​

✅ Switch Therapeutics - announced a $52 million investment in March 2024 for developing targeted siRNA therapies using advanced nanotechnology and RNA interference, accelerating its nucleic acid-based therapy pipeline.​

✅ Evonik and ST Pharm - in April 2025, combined expertise in pDNA/mRNA manufacturing and LNP formulation to scale RNA therapeutic services, positioning both as premium mRNA-based therapeutic providers.​

✅ TransCode Therapeutics - collaborated with Debiopharm in January 2024 to develop nucleic acid therapeutics leveraging Debiopharm's drug delivery technologies, aiming at cancer and infectious diseases treatments.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=nucleic-acid-therapeutics-market?ram (Purchase 2 or more Reports and get 50% Discount)

Growth Drivers:

-Rising prevalence of chronic and genetic diseases such as cancer, cardiovascular diseases, and monogenetic disorders which increase demand for targeted gene therapies.

-Advancements in gene cloning techniques and RNA technologies boosting the development of effective nucleic acid therapeutics.

-Growing investments in biotechnology and pharmaceutical companies focusing on nucleic acid-based drug development.

-Increasing adoption of RNA-based therapeutics for treatment of previously untreatable conditions including autoimmune and infectious diseases.

-Expansion of clinical trials and regulatory support accelerating the approval of nucleic acid therapies.

-Rising awareness and improved healthcare infrastructure facilitating the delivery and acceptance of these advanced therapies globally.

Market Segmentation Analysis:

-By Category

Antisense Oligonucleotides (ASOs): Short single-stranded DNA/RNA molecules targeting specific mRNA for gene silencing, prominent in genetic and infectious disease treatments.

Small Interfering RNA (siRNA): Double-stranded RNA molecules that mediate mRNA degradation, used in cancer and viral infection therapies.

Messenger RNA (mRNA): Used primarily in vaccines and protein replacement therapies, gaining prominence due to COVID-19 vaccine success.

Self-Amplifying RNA (saRNA): An emerging RNA technology that amplifies itself inside cells to increase therapeutic protein expression.

-By Application

Cancers: Largest application segment benefiting from targeted gene therapies.

Viral Infections: Includes antiviral therapeutics and vaccines based on nucleic acids.

Genetic Disorders: Treatments focusing on correcting gene expression in rare and common inherited conditions.

Others: Include autoimmune diseases, cardiovascular diseases, and metabolic disorders.

-By End User

Hospitals: Major users delivering advanced therapeutics and clinical trials.

Academic & Research Institutes: Key contributors to R&D, clinical validation, and innovation in nucleic acid therapeutics.

Regional Insights:

North America: This region dominates the nucleic acid therapeutics market with the largest share, estimated around USD 6.18 to 6.44 billion in 2025. The United States leads with approximately 86% of the North American market share, driven by advanced healthcare infrastructure, significant R&D investments, a strong biotechnology ecosystem, and supportive regulatory frameworks. Key pharmaceutical and biotech companies actively developing innovative nucleic acid therapies bolster this dominance. Canada also contributes through government-backed genomic research initiatives. The strong presence of personalized medicine, gene-editing advancements, and therapies targeting genetic disorders further fuel growth.​

Asia-Pacific: Expected to register the fastest growth in the forecast period due to rising incidences of chronic and genetic diseases, increasing healthcare expenditure, and expanding biopharmaceutical investments. Countries such as China, India, and Japan emerge as key markets. The region benefits from rising awareness, government healthcare investments, a growing aging population, and the cost advantage in manufacturing. Key drivers include RNA-based therapeutics' effectiveness for prevalent diseases like cardiovascular conditions and increased adoption of innovative technologies.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/nucleic-acid-therapeutics-market?ram

Key Players:

Ionis Pharmaceuticals | Alnylam Pharmaceuticals, Inc. | Gilead Sciences, Inc. | AstraZeneca | Sarepta Therapeutics, Inc. | Creative Biolabs | GSK plc | Novartis AG | BioNTech SE | Silence Therapeutics

Key Highlights (Top 5 Key Players) for Nucleic Acid Therapeutics Market:

-Ionis Pharmaceuticals reported revenue of approximately USD 452 million in Q2 2025, with a strong growth trajectory driven by RNA-based therapies and multiple strategic partnerships unlocking multi-billion-dollar potential markets.

-Alnylam Pharmaceuticals, a major player alongside Ionis, is recognized for its expanding product portfolio in RNA therapeutics, contributing significantly to the estimated Nucleic Acid Therapeutics Market size of about USD 6.39 billion in 2025.

-Sarepta Therapeutics is another key contributor to the market, with major investments in innovative RNA-based treatments targeting rare and genetic disorders within the expanding global market.

-Novartis AG holds a substantial presence in the nucleic acid therapeutics field, part of the estimated global market size of USD 6.39 billion in 2025, leveraging research in RNA interference and gene editing technologies.

-BioNTech SE, also a top player, plays a crucial role in RNA-based therapeutic development, contributing to the market growth expected to reach USD 12.46 billion by 2030, highlighting strong demand for precision medicine solutions.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.